Cosentyx label update for scalp psoriasis

[Fred]

Novartis have announced a label update to the use of Cosentyx for scalp psoriasis in the USA.

Quote:

---

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab) The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis - one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.

Source: novartis,com